Xience 5

The Absorb BVS (Abbott Vascular, Santa Clara, USA) is a fully bioresorbable vascular scaffold which consists of a fully biodegradable poly-L-lactide (PLLA) platform covered by an amorphous matrix of poly-D,L-lactide (PDLLA) and everolimus. It is gradually resorbed in the process of hydrolysis to non-inflammatory products, such as CO₂ or H₂O [3 ]. The average strut thickness is 157 µm. Eighty percent of drug release occurs within 30 days.
The Xience V (Abbott Vascular, CA, USA) is a cobalt-chromium stent coated with a non-erodible fluoropolymer loaded with 100 μg/cm² of everolimus. The thickness of the metallic struts and coating combined is approximately 90 µm (81 µm for the stent and 7.8 µm for the polymer ≈ 90) [8 ]. The antiproliferative drug concentration and release profile are similar in both stents.

We combined data from 7 prospective, randomized trials enrolling patients with second‐generation DES that were maintained at the Cardiovascular Research Foundation (New York, NY) in which treated lesion ACC/AHA class was determined at an angiographic core laboratory. The data that support the findings of this study are available from the corresponding author upon reasonable request. Clinical follow‐up was performed for up to 5 years. The designs of the trials have been previously described and are summarized in Supplemental Table S1.¹⁰, ¹¹, ¹², ¹³, ¹⁴, ¹⁵, ¹⁶ As we sought to study contemporary DES outcomes, only patients in which a single lesion was treated with a contemporary second‐generation DES (Xience V or Xience Prime, Abbott Vascular, Santa Clara, CA; Promus, Boston Scientific, Marlborough, MA; Nobori, Terumo, Tokyo, Japan; and Resolute Integrity, Medtronic, Santa Rosa, CA) were included in the analysis. Patients were censored at time of first event or at last follow‐up time, whichever occurred first. Each trial was approved by the institutional review board or ethics committee at the respective participating centers, and all patients signed written informed consent before randomization.